Drugs / CE-Iohexol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04627831 | Jan 2022 → Mar 2023 | — | Ligand Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CE-Iohexol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627831 ↗ |
| Modality | Diagnostic / imaging agent | “Captisol-Enabled™ Iohexol as needed for the diagnostic procedure” NCT04627831 ↗ |